Showing 1,441 - 1,460 results of 39,062 for search '(( 5 ((step decrease) OR (mean decrease)) ) OR ( 100 ((teer decrease) OR (a decrease)) ))', query time: 0.90s Refine Results
  1. 1441

    The search strategy in three databases. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  2. 1442

    A summary of the included study characteristics. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  3. 1443

    NIH score. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  4. 1444

    List of excluded studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  5. 1445
  6. 1446
  7. 1447
  8. 1448
  9. 1449
  10. 1450
  11. 1451

    S100A9: A Potential Biomarker for the Progression of Non-Alcoholic Fatty Liver Disease and the Diagnosis of Non-Alcoholic Steatohepatitis by Xiaolin Liu (403100)

    Published 2015
    “…We find that gene expression of s100a9 was higher in NAFL group compared with control, and was increased in NASH groups and decreased in NAFL + T2DM group compared with NAFL. …”
  12. 1452
  13. 1453
  14. 1454

    Adjustment step size. by Qingnan Ji (22662198)

    Published 2025
    “…Integration efficiency increases by 18.7%, and computational complexity is significantly reduced, with average computation time decreased by 15.4%. User satisfaction also improves, with a 19.5% increase in experience ratings. …”
  15. 1455
  16. 1456
  17. 1457
  18. 1458
  19. 1459
  20. 1460

    Effects of siRNA TMPRSS2-ERG on ERG protein expression and cell viability. by Giorgia Urbinati (554921)

    Published 2015
    “…The number of viable cells was measured and 100% cell viability corresponds to the number of living cells incubated only with transfecting agent. *** = <i>p</i><0.001, significant decrease compared to untreated cells or to siRNA Control (Kruskal & Wallis followed by Tukey and Dunnet test).…”